Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) on tetanus toxoid-specific CD4+ T cells is a heterodimeric surface protein complex that specifically recognizes peptides derived from the tetanus toxoid (TT) protein when presented by Major Histocompatibility Complex (MHC) class II molecules (Meuer et al., 1983, Nature). This recognition event is the cornerstone of the secondary immune response to Clostridium tetani, leading to the activation and clonal expansion of memory T-helper cells (Geiger et al., 2009, Journal of Experimental Medicine). These receptors are characterized by their high affinity for TT epitopes, which allows for the rapid induction of cytokines such as IL-2 and IFN-gamma upon re-exposure to the antigen (Bacher et al., 2013, Journal of Immunology). In clinical research, these TCRs are frequently used as a gold standard for validating T-cell assays and monitoring the efficacy of vaccine platforms due to the high prevalence of TT-specific immunity in the general population (Rosendahl Huber et al., 2014, Clinical & Experimental Immunology). While not a traditional drug target for small molecules, these TCRs are increasingly relevant in the development of TCR-engineered T-cell therapies and as targets for antigen-specific immunotherapy (Sallusto et al., 2018, Nature Reviews Immunology). The primary interaction occurs with the tetanus toxoid antigen, which serves as the ligand that triggers the receptor's signaling pathway during vaccination.
The TCR recognizes specific tetanus toxoid peptides presented by MHC Class II molecules, initiating a signaling cascade through the CD3 complex that leads to T-cell differentiation and memory formation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor on tetanus toxoid-specific CD4+ T cells (TT-specific TCR).